Skip to Content

Rallybio Corp RLYB

Morningstar Rating
$1.85 +0.26 (16.35%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RLYB is trading within a range we consider fairly valued.
Price
$1.49
Fair Value
$2.35
Uncertainty
Extreme
1-Star Price
$69.33
5-Star Price
$9.43
Economic Moat
Sjtws
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RLYB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.59
Day Range
$1.591.86
52-Week Range
$1.239.14
Bid/Ask
$1.61 / $1.85
Market Cap
$69.95 Mil
Volume/Avg
241,377 / 217,891

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
43

Comparables

Valuation

Metric
RLYB
IMVT
DYN
Price/Earnings (Normalized)
Price/Book Value
0.666.9019.12
Price/Sales
Price/Cash Flow
Price/Earnings
RLYB
IMVT
DYN

Financial Strength

Metric
RLYB
IMVT
DYN
Quick Ratio
11.8721.562.41
Current Ratio
12.3922.142.53
Interest Coverage
Quick Ratio
RLYB
IMVT
DYN

Profitability

Metric
RLYB
IMVT
DYN
Return on Assets (Normalized)
−43.05%−43.33%−88.69%
Return on Equity (Normalized)
−45.88%−47.83%−114.25%
Return on Invested Capital (Normalized)
−50.14%−52.69%−102.56%
Return on Assets
RLYB
IMVT
DYN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWchwxlldMkcm$570.1 Bil
VRTX
Vertex Pharmaceuticals IncPzlqzckXyhdm$108.0 Bil
REGN
Regeneron Pharmaceuticals IncSgctwdxwYfmbky$105.6 Bil
MRNA
Moderna IncJzcqfkrzdBqdv$40.8 Bil
ARGX
argenx SE ADRTznhptqhbTydpj$23.5 Bil
BNTX
BioNTech SE ADRGjclycnsVbk$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncFdmdtcmjPsvwwys$18.8 Bil
BMRN
Biomarin Pharmaceutical IncNkmjbgfpHwblbfl$16.5 Bil
RPRX
Royalty Pharma PLC Class AJcgywzcbgnPvgzftm$13.6 Bil
INCY
Incyte CorpPmgbsnqypBylzgjy$12.8 Bil

Sponsor Center